FDA
-
-
-
-
-
-
-
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
-
-
-
-
-
-
-
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
-
-
-
-
-
-
-
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
-
-
-
-
-
-
-
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
-
335,704 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


